Lisa Drake – MRI Results from Dry Fasting & HBOT Experiment

Lisa shared her MRI results after a three-week experimental protocol combining dry fasting and Hyperbaric Oxygen Therapy (HBOT). Out of the three weeks, she dry fasted for a total of 11 days (mostly in 2–3 day blocks followed by refeeding).

While the tumour was not fully eliminated, there was a further reduction in mass compared to previous imaging (no exact measurements provided). Lymph nodes remain clear, and there has been no disease progression despite periods of dietary non-compliance.

Lisa notes that extended fasting is often cited as necessary to fully trigger autophagy and cell cannibalism, but as she is very lean, she limits fasts to 4 days maximum before refeeding. She also suspects tumour resistance factors, such as MDR1 overexpression, may play a role in limiting impact.

✅ Supplements & Compounds

No specific compounds during fasting phase; paused ReDO protocol drugs to give the liver a rest
Normally uses ReDO Project repurposed drugs in her broader protocol
Will consider reintroducing supplements and off-labels after returning from travel

✅ Therapies & Strategies

Dry fasting – 11 days total over 3 weeks (in 2–3 day blocks)
HBOT – multiple sessions during the 3-week period
Refeeding phases between fasts for weight and energy recovery
Travel and sun exposure during protocol break in Florida
Considering next-stage protocol adjustments after weight and muscle recovery

✅ Lab Testing & Monitoring

MRI – confirmed tumour mass reduction (degree unspecified) and no lymph node involvement
Subjective monitoring of energy levels, muscle mass, and weight

✅ Resources & References Shared

MDR1 overexpression research in relation to tumour resistance
ReDO Project information on repurposed cancer drugs
Peer discussion on GKI, MCT oil, exogenous ketones, protein balance, and muscle rebuilding strategies

✅ Key Takeaways

Even short fasting cycles combined with HBOT may contribute to tumour reduction and stability.
Maintaining sufficient body mass is critical when fasting, especially for already lean individuals.
MDR1 overexpression may limit the effects of certain metabolic interventions, warranting tailored strategies.
Pausing certain drugs or supplements during fasting may help protect organ function but could impact protocol potency.
Ongoing experimentation, testing, and adaptation remain central to Lisa’s approach.

Original Post

0 comments